Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

This study has been terminated.
(PI and lab have re-located study to The Ohio State University)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Thomas Cherpes, DVM, MD, The Ohio State University Identifier:
First received: December 10, 2012
Last updated: January 5, 2014
Last verified: January 2014
The investigators are conducting a research study to understand how cells responsible for fighting infection (immune cells) are affected by hormonal contraceptive use. The investigators hypothesize that progestin-containing hormonal contraceptives (i.e., Depo-Provera) inhibit host response to infection. To test this hypothesis, the investigators will collect blood and genital tract samples from women before and after their initiation of a hormonal contraceptive (either birth control pills, Depo-Provera, or Mirena).

Condition Intervention
Initiation of Oral Contraception (OC)
Initiation of Depo-Provera (DMPA)
Initiation of Mirena (LNG-IUD)
Drug: Mirena
Drug: Oral contraception
Drug: Depo-Provera

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

Resource links provided by NLM:

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • Proliferative capacity (i.e., ability to respond to antigen stimulation) of T cells isolated from the cervix of women before and after initiating a hormonal contraceptive [ Time Frame: Prior to and ~ 1 month (but up to 2 months) after initiation of a hormonal contraceptive ]

Enrollment: 7
Study Start Date: December 2012
Study Completion Date: June 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Women who choose to initiate Depo-Provera
Drug: Depo-Provera
Women who choose to initiate Mirena (intrauterine device)
Drug: Mirena
Oral contraception
Women who choose to initiate oral contraception
Drug: Oral contraception


Ages Eligible for Study:   15 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Women interested in initiating hormonal contraceptive use

Inclusion Criteria:

  1. 15-25 years of age (inclusive)
  2. History of regular menstrual cycle
  3. Not pregnant
  4. No plan to become pregnant in the next 3 months
  5. Interested in beginning use of OC, DMPA, or LNG-IUD
  6. Able to read and provide written informed consent (and consent from a parent/guardian if the participant is a minor)

Exclusion Criteria:

  1. Anticipated move out of area that prevents return for a follow-up visit
  2. Unavailability for follow-up visit
  3. Less than 90 days post-partum or post-abortion
  4. Sexually transmitted infection (STI) diagnosed less than 30 days prior to enrollment
  5. Use of OC, contraceptive ring or patch, single rod implant, LNG-IUD, or copper-containing IUD less than 3 months prior to enrollment
  6. DMPA injection less than 6 months prior to enrollment
  7. History of immunosuppressive condition of current use of immunosuppressive medications
  8. History of a cervical malignancy
  9. Detection of cervical anatomic pathologic conditions that preclude cervical biopsy procurement
  10. Intolerance or contradiction to use of OC, DMPA, or LNG-IUD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01750476

United States, Pennsylvania
UPMC Adolescent Clinic of Oakland
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Thomas Cherpes, DVM, MD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigator: Thomas L. Cherpes, MD assistant professor
  More Information

Responsible Party: Thomas Cherpes, DVM, MD, Associate Professor, The Ohio State University Identifier: NCT01750476     History of Changes
Other Study ID Numbers: PRO12010187
R01HD072663 ( US NIH Grant/Contract Award Number )
Study First Received: December 10, 2012
Last Updated: January 5, 2014

Keywords provided by Ohio State University:
oral contraception

Additional relevant MeSH terms:
Medroxyprogesterone Acetate
Contraceptive Agents
Contraceptive Agents, Female
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Male
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Contraceptives, Oral, Synthetic
Contraceptives, Oral processed this record on May 23, 2017